A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia

Colaboración

Año: 2017

Garcia-Gutierrez, V; Gomez-Casares, MT; Puerta, JM; Alonso-Dominguez, JM; Osorio, S; Hernandez-Boiuda, JC; Collado, R; Ramirez, MJ; Ibanez, F; Martin, ML; Rodriguez-Gambarte, JD; Martinez-Laperche, C; Gomez, M; Fiallo, DV; Redondo, S; Rodriguez, A; Ruiz-Nuno, C; Steegmann, JL; Jimenez-Velasco, A

Título: PLOS ONE

• Q1